411
Participants
Start Date
September 1, 2019
Primary Completion Date
September 5, 2020
Study Completion Date
October 5, 2020
bictegravir/emtricitabine/tenofovir alafenamide
Treatment experienced patients with HIV infection that switched to a bictegravir/emtricitabine/tenofovir alafenamide-based ART regimen
Thomas Jefferson University, Philadelphia
Collaborators (1)
University of Maryland, College Park
OTHER
Indiana University Health
OTHER
The Brooklyn Hospital Center
OTHER
University of Illinois at Chicago
OTHER
Nova Southeastern University
OTHER
University of California, San Francisco
OTHER
Thomas Jefferson University
OTHER